on Theranexus (EPA:ALTHX)
THX Pharma and Exeltis Advance Toward Commercialization of TX01
THX Pharma (Theranexus) and Exeltis have reached a milestone in the commercialization of TX01, intended for Gaucher and Niemann-Pick type C diseases. On October 14, 2025, the two companies announced the progress of their regulatory filing project.
This partnership facilitates the planned launch of TX01 in Europe in 2027, followed by Latin America and the Middle East. With this success, THX Pharma could receive payments contingent on additional regulatory milestones.
TX01, derived from an approved compound, is a symbol of their commitment to addressing unmet medical needs. Mathieu Charvériat, CEO of THX Pharma, and Salustiano Perez, CEO of Exeltis, see a promising future for this innovative treatment.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news